Phase II trial of the association of a methionine-free diet with cystemustine therapy in melanoma and glioma

Anticancer Research

Volumn 29, Issue 12, 2009, Pages 5235-5240

  Thivat, Emilie ^a,b,c   Farges, Marie Chantal ^d   Bacin, Franck ^d,e   D'Incan, Michel ^c,d,f   Mouret Reynier, Marie Ange ^a,b,c,d   Cellarier, Eric ^a,c   Madelmont, Jean Claude ^c   Vasson, Marie Paule ^a,d   Chollet, Philippe ^a,b,c,d   Durando, Xavier ^a,b,c,d  

^a CENTRE JEAN PERRIN   (France)

^b Centre d'Investigation Clinique   (France)

^c Equipe Accueil No4231   (France)

^d UNIVERSITÉ CLERMONT AUVERGNE   (France)

^e SERVICE DE RHUMATOLOGIE   (France)

^f HÔTEL DIEU   (France)

Author keywords

CENU; Glioma; Melanoma; Methionine free diet; Nitrosourea

Indexed keywords

CYSTEMUSTINE; METHIONINE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLIOMA; HUMAN; LEUKOPENIA; LIVER TOXICITY; MALE; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NUTRITIONAL ASSESSMENT; NUTRITIONAL STATUS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHOROID NEOPLASMS; COMBINED MODALITY THERAPY; DIET; FEMALE; GLIOMA; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; METHIONINE; MIDDLE AGED; NEOPLASM STAGING; NITROSOUREA COMPOUNDS; NUTRITIONAL STATUS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 75149120166     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Avril MF, Namer M, Bonneterre J, Kerbrat P, Bonerandi JJ et al: Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66: 1873-1878, 1990.
2. Bajetta E, Del Vecchio M, Bernard-Marty C, Vitali M, Buzzoni R, Rixe O, Nova P, Aglione S, Taillibert S and Khayat D: Metastatic melanoma: chemotherapy. Semin Oncol 29: 427-445, 2002.
3. Galanis E and Buckner JC: Chemotherapy of brain tumors. Curr Opin Neurol 13: 619-625, 2000.
4. 2: a phase II trial. Anticancer Drugs 16: 1003-1007, 2005.
5. Belanich M, Pastor M, Randall T, Guerre D, Kibitel J, Alas L, Li B, Citron M, Wasserman P, White A, Eyre H, Jaeckle K, Schulman S, Rector D, Prados M, Coons S, Shapiro W and Yarosh D: Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 56: 783-788, 1996.
6. Halpern BC, Clark BR, Hardy DN, Halpern RM and Smith RA: The effect of replacement of methionine by homocystine on survival of malignant and normal adult mammalian cells in culture. Proc Natl Acad Sci USA 71: 1133-1136, 1974.
7. Stern PH and Hoffman RM: Enhanced in vitro selective toxicity of chemotherapeutic agents for human cancer cells based on a metabolic defect. J Natl Cancer Inst 76: 629-639, 1986.
8. Breillout F, Antoine E and Poupon MF: Methionine dependency of malignant tumors: a possible approach for therapy. J Natl Cancer Inst 82: 1628-1632, 1990.
9. Guo HY, Herrera H, Groce A and Hoffman RM: Expression of the biochemical defect of methionine dependence in fresh patient tumors in primary histoculture. Cancer Res 53: 2479-2483, 1993.
10. Cellarier E, Durando X, Vasson MP, Farges MC, Demiden A, Maurizis JC, Madelmont JC and Chollet P: Methionine dependency and cancer treatment. Cancer Treat Rev 29: 489-499, 2003.
11. Poirson-Bichat F, Goncalves RA, Miccoli L, Dutrillaux B and Poupon MF: Methionine depletion enhances the antitumoral efficacy of cytotoxic agents in drug-resistant human tumor xenografts. Clin Cancer Res 6: 643-653, 2000.
12. Kokkinakis DM, Hoffman RM, Frenkel EP, Wick JB, Han Q, Xu M, Tan Yand Schold SC: Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice. Cancer Res 61: 4017-4023, 2001.
13. Goseki N and Endo M: Thiol depletion and chemosensitization on nimustine hydrochloride by methionine-depleting total parenteral nutrition. Tohoku J Exp Med 161: 227-239, 1990.
14. Morvan D, Papon J, Madelmont JC and Demidem A: Methionine deprivation potentiates the effect of cystemustine treatment on B16 melanoma tumor in syngenic recipients. AACR Proceedings 2002, 3822, 2002.
15. Durando X, Thivat E, Farges MC, Cellarier E, D'Incan M, Demidem A, Vasson MP, Barthomeuf C and Chollet P: Optimal methionine-free diet duration for nitrosourea treatment: a phase I clinical trial. Nutr Cancer 60: 23-30, 2008.
16. 2 as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group. Melanoma Res 9: 607-610, 1999.
17. Durando X, Thivat E, Roche H, Bay JO, Lemaire JJ, Verrelle P, Chazal J, Cure H and Chollet P: Cystemustine in recurrent high grade glioma. J Neurooncol 79: 33-37, 2006.
18. WHO Handbook for Reprinting Results of Cancer Treatment. WHO Offset Publication No. 48. Neoplasma 20: 37-46, 1990.
19. Minet-Quinard R, Van Praagh I, Kwiatkowski F, Beaujon G, Feillel V, Beaufrere B, Bargnoux PJ, Cynober L and Vasson MP: Pre- and postoperative aminoacidemia in breast cancer: a study vs. matched healthy subjects. Cancer Invest 22: 203-210, 2004.
20. Kwiatkowski F, Girard M, Hacene K and Berlie J: SEM: A suitable statistical software adaptated for research in oncology. Bull Cancer 10: 715-721, 2000.
21. Goseki N, Yamazaki S, Shimojyu K, Kando F, Maruyama M, Endo M, Koike M and Takahashi H: Synergistic effect of methionine-depleting total parenteral nutrition with 5-fluorouracil on human gastric cancer: a randomized, prospective clinical trial. Jpn J Cancer Res 86: 484-489, 1995.
22. Epner DE, Morrow S, Wilcox M and Houghton JL: Nutrient intake and nutritional indexes in adults with metastatic cancer on a phase I clinical trial of dietary methionine restriction. Nutr Cancern 42: 158-166, 2002.
23. Thivat E, Durando X, Demidem A, Farges MC, Rapp M, Cellarier E, Guenin S, D'Incan M, Vasson MP and Chollet P: A Methionine-free diet associated with nitrosourea treatment down-regulates methylguanine-DNA methyl transferase activity in patients with metastatic cancer. Anticancer Res 27: 2779-2783, 2007.
24. Urosevic V, Chollet P, Adenis A, Chauvergne J, Fargeot P, Roche H, Kerbrat P, Lentz MA, Fumoleau P and Chevallier B: Results of a phase II trial with cystemustine in advanced malignant melanoma. A trial of the EORTC Clinical Screening Group. Eur J Cancer 32: 181-182, 1996.
25. Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, Papadopoulos N and Benjamin RS: Treatment of uveal melanoma metastatic to the liver: a review of the M.D. Anderson Cancer Center experience and prognostic factors. Cancer 76: 1665-1670, 1995.
26. Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SM, Finn SM, Munzenrider JE and Spar MD: Survival of patients with metastases from uveal melanoma. Ophthalmology 98: 383-389, 1991.
27. Kath R, Hayungs J, Bornfeld N, Sauerwein W, Höffken K and Seeber S: Prognosis and treatment of disseminated uveal melanoma. Cancer 72: 2219-2223, 1993.
28. Lens MB and Eisen TG: Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin Pharmacother 4: 2205-2211, 2003.
29. Lakshmanan FL, Perera WD, Scrimshaw NS and Young VR: Plasma and urinary amino acids and selected sulfur metabolites in young men fed a diet devoid of methionine and cystine. Am J Clin Nutr 29: 1367-1371, 1976.
30. Kokkinakis DM, Wick JB and Zhou QX: Metabolic response of normal and malignant tissue to acute and chronic methionine stress in athymic mice bearing human glial tumor xenografts. Chem Res Toxicol 15: 1472-1479, 2002.
31. Tan Y, Zavala J Sr, Han Q, Xu M, Sun X, Tan X, Tan X, Magana R, Geller J and Hoffman RM: Recombinant methioninase infusion reduces the biochemical endpoint of serum methionine with minimal toxicity in high-stage cancer patients. Anticancer Res 17: 3857-3860, 1997.
32. Yang Z, Wang J, Yoshioka T, Li B, Lu Q, Li S, Sun X, Tan Y, Yagi S, Frenkel EP and Hoffman RM: Pharmacokinetics, methionine depletion, and antigenicity of recombinant methioninase in primates. Clin Cancer Res 10: 2131-2138, 2004.
33. Yang Z, Wang J, Lu Q, Xu J, Kobayashi Y, Takakura T, Takimoto A, Yoshioka T, Lian C, Chen C, Zhang D, Zhang Y, Li S, Sun X, Tan Y, Yagi S, Frenkel EP and Hoffman RM: PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates. Cancer Res 64: 6673-6678, 2004.